Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

Sensor augmented pump therapy




There are three main components to Sensor Augmented Therapy: a ‘smart’ Insulin Pump, a Continuous Glucose Monitoring (CGM) system and therapy management software. This system^ incorporates innovative CGM features like predictive alerts to prevent dangerous hypo or hyperglycaemic glucose events. Some systems will automatically suspend insulin if a patient is likely to have an event, for greater patient safety.    

How to prevent hypo and hyperglycaemic events

MiniMed® 640G provides better control
The most advanced system on the market (as at November 2015), the MiniMed® 640G Insulin Pump System^ with SmartGuard™ features technology that closely mimics the way a healthy pancreas delivers basal insulin to the body – giving your patients better control.

The sensor sits under the skin in the interstitial fluid, where cells get oxygen and nutrients, including glucose. They are easily inserted using an automatic insertion device, like many types of infusion sets, a needle is used to insert the glucose sensor. The needle is then removed, leaving just the tiny flexible electrode under the skin.

The Insulin Pump acts as the receiver of the CGM data sent wirelessly from the sensor by the transmitter.

  • Maximum high alarm thresholds can be set as high as 22.2 mmol/L and the minimum low alarm threshold can be set as low as 2.2 mmol/L
  • The glucose sensor should avoid recent infusion sites and should be worn according to:
  • The patient’s desired comfort level
  • Individual preference
  • The patient’s experience.


Benefits of CGM

What are the benefits of CGM?

CGM reduces HbA1c and improves glycaemic control. Several randomised controlled trials12,17,18 showed that CGM can lead to:

  • Up to 1% HbA1c reduction without increasing the rate of severe hypoglycaemia
  • Tighter glycaemic control
  • Greater number of patients reaching the HbA1c target recommended by the American Diabetes Association (ADA)

All of these benefits can help patients achieve better control over diabetes.

The advantages of CGM over traditional fingerstick testing and HbA1c testing are well documented
Research has shown that:

  • 60% of glucose lows may not be revealed with fingerstick testing alone19
  • CGM identifies four times as many serious glucose incidents as self-monitoring of blood glucose (SMBG)19
  • CGM can significantly reduce HbA1c and has been shown to reduce HbA1c levels by up to 1% when compared with fingerstick testing alone12

How your patients can benefit

CGM can be very beneficial, especially for parents and people with a busy lifestyle.

  • Parents can have greater peace of mind, knowing they don’t have to check on their child through the night if they have a system that can automatically suspend insulin
  • Sports enthusiasts and students can concentrate on competing or taking their exams
  • Busy workers can get on with their day-to-day activities with less anxiety
  • Women who are pregnant or are thinking about becoming pregnant, can feel more reassured

Discover whether your patient is eligible for funding from the CGM Initiative.

Learn more

12. Bergenstal RM, Tamborlane WV, Ahmann A, et al. The STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in Insulin Dependent Diabetes. N Engl J Med. 2010;363(4):311-320.

17. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-1476.

18. Raccah D, Sulmont V, Resnik Y,et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend Study. Diabetes Care. 2009;32(12):2245-2250.

19. Kaufman FR, et al. A pilot study of continuous glucose monitoring system. Diab Care. 2001:24:2030-2034 2. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin Pump Therapy in Insulin Dependent Diabetes NEJM. 2010;363(4):311-320  

^Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology.